We have listed a number of clinical studies and papers by various industry leaders. Please click on your chosen paper to read more.
GlucoMen Areo and Areo 2K
Accuracy Performance Data
GlucoMen Areo and Areo 2K accuracy data, exceeding the requirements of ISO 15197:2015
Independent Accuracy Evaluation – Francesca Berti, PhD1, Cosimo Scuffi, MSc1, and Francesco Valgimigli, PhD1
An independent accuracy evaluation published in JDST (Journal of Science and Diabetes Technology)
“Accuracy Evaluation of Two Blood Glucose Monitoring Systems Following ISO 15197:2013”
TUV Certificate of ISO compliance
GlucoMen LX2 and LX PLUS
GlucoMen LX PLUS – Accuracy Evaluation Data
GlucoMen LX PLUS Haematocrit Study
Accuracy evaluations of our GlucoMen LX PLUS and LX2 meters
Diabetic Ketoacidosis
Sick day management – Laffel 2005
An assessment of sick day management comparing blood ketone testing with urine testing
Can we prevent DKA in children? – Laffel 2007
A study looking at sick day management, early identification and treatment of DKA.
Recent advances in DKA management – Matthews & Wallace 2004
Looking at the management of DKA and near patient testing
Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome – Diabetes Spectrum
Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic syndrome (HHS) are two acute complications of diabetes that can result in increased morbidity and mortality if not efficiently and effectively treated.
BSPED recommended DKA guidelines – British Society of Paediatric Endocrinology and Diabetes 2009
Guidelines for the Management of Diabetic Ketoacidosis
General
ISO 15197:2013 Accuracy Requirements
Information brochure detailing full requirements and criteria of ISO 15197:2013, how evaluations must be performed and how results must be presented in order for blood glucose meters to comply
Haematocrit Interference – Mainz Report
Taking a look at haematocrit interference when taking a reading from blood glucose meters
Management of hyperglycemia in type 2 diabetes – ADA & EASD 2012
ADA and EASD recommendations for anti-hyperglycemic therapy for adults with type 2 diabetes
